Biogen BIIB FLIXABI — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biogen's flixabi — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biogen's FLIXABI — total revenue?
- Biogen (BIIB) reported FLIXABI — total revenue of $10.5M in Q1 2026.
- How has Biogen's FLIXABI — total revenue changed year-over-year?
- Biogen's FLIXABI — total revenue decreased by 19.8% year-over-year, from $13.1M to $10.5M.
- What is the long-term trend for Biogen's FLIXABI — total revenue?
- Over 4 years (2021 to 2025), Biogen's FLIXABI — total revenue has grown at a -14.7% compound annual growth rate (CAGR), from $99.4M to $52.6M.
- What does FLIXABI — total revenue mean?
- This metric represents the total gross revenue generated from the sale of the biosimilar product Flixabi. It reflects the market adoption and commercial performance of this specific therapeutic asset within the company's broader portfolio. Monitoring this revenue stream helps assess the competitive positioning of biosimilar offerings against reference biologics and other market entrants.